IRON DYNAMICS IN HEMODIALYSIS PATIENTS RECEIVING EPOETIN-BETA OR CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (CERA)

被引：0
|
作者：
Horie, Masanobu [1 ]
Hasegawa, Eizou [1 ]
Minoshima, Ken-ichi [1 ]
Shimonaka, Yasushi [2 ]
机构：
[1] Daiyukai Daiichi Hosp, Dept Urol, Ichinomiya, Jordan
[2] Chugai Pharmaceut Co Ltd, Prod Res Dept, Kamakura, Kanagawa, Japan
来源：
NEPHROLOGY DIALYSIS TRANSPLANTATION | 2013年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R3 [基础医学]; R4 [临床医学];
学科分类号：
1001 ; 1002 ; 100602 ;
摘要：
引用
收藏
页码：242 / 242
页数：1
相关论文
共 50 条
  • [1] Monthly Continuous Erythropoietin Receptor Activator Versus Weekly Epoetin-Beta, Similar Hemoglobinization but Different Anisocytosis Degree in Hemodialysis Patients: A Randomized Controlled Trial
    Uriol-Rivera, Miguel G.
    Obrador-Mulet, Aina
    Jimenez-Mendoza, Sonia
    Corral-Baez, Antonio
    Perianez-Parraga, Leonor
    Garcia-Alvarez, Angel
    de la Prada, Francisco J.
    [J]. JOURNAL OF HEMATOLOGY, 2021, 10 (06) : 255 - 265
  • [2] Influence of continuous erythropoietin receptor activator (CERA) administration intervals on erythropoietic effect in hemodialysis patients
    Daimon S.
    Nuka H.
    Kitada K.
    Suzuki Y.
    Kim F.
    Kawano M.
    [J]. Renal Replacement Therapy, 2 (1)
  • [3] HEMOGLOBIN VARIABILITY WITH EPOETIN BETA AND CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR IN PATIENTS ON PERITONEAL DIALYSIS
    Selby, Nicholas M.
    Fonseca, Sally A.
    Fluck, Richard J.
    Taal, Maarten W.
    [J]. PERITONEAL DIALYSIS INTERNATIONAL, 2012, 32 (02): : 177 - 182
  • [4] Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease
    Vega, A.
    Abad, S.
    Verdalles, U.
    Aragoncillo, I
    Velazquez, K.
    Quiroga, B.
    Escudero, V
    Lopez-Gomez, J. M.
    [J]. HIPPOKRATIA, 2014, 18 (04) : 315 - 318
  • [5] LONG-TERM INTRAVENOUS CERA (CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR) MAINTAINS HEMOGLOBIN CONCENTRATIONS IN HEMODIALYSIS PATIENTS
    Besarab, Anatole
    Beyer, Ulrich
    Dougherty, Frank C.
    [J]. NEPHROLOGY, 2005, 10 : A312 - A313
  • [6] Epoetin β pegol (continuous erythropoietin receptor activator, CERA) is another choice for the treatment of anemia in myelodysplastic syndrome: A case report
    Ikenoue T.
    Naito H.
    Kitamura T.
    Hattori H.
    [J]. Journal of Medical Case Reports, 11 (1)
  • [7] ANALYSIS OF FACTORS ASSOCIATED WITH THE DOSE OF CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (CERA) IN PD PATIENTS
    Yasuhiro, Suzuki
    Masashi, Mizuno
    Humiko, Sakata
    Hiroshi, Kinashi
    Shoichi, Maruyama
    Seiichi, Matsuo
    Yasuhiko, Ito
    [J]. NEPHROLOGY, 2014, 19 : 111 - 111
  • [8] Effects of Continuous Erythropoietin Receptor Activator (CERA) in Kidney Transplant Recipients
    Esposito, C.
    Abelli, M.
    Sileno, G.
    Migotto, C.
    Torreggiani, M.
    Serpieri, N.
    Maggi, N.
    Esposito, V.
    Grosjean, F.
    Scaramuzzi, M. L.
    Montagna, F.
    Canton, A. D.
    [J]. TRANSPLANTATION PROCEEDINGS, 2012, 44 (07) : 1916 - 1917
  • [9] DOSING OF CONTINUOUS ERYTHROPOIETIN RECEPTOR ACTIVATOR (CERA) ONCE MONTHLY VS DARBEPOETIN, EPOETIN ALFAOR EPOETIN BETA IN HIGH-RISK PATIENTS WITH CHRONIC KIDNEY DISEASE ON DIALYSIS: AN ANALYSIS OF 13 INTERNATIONAL TRIALS
    Locatelli, Francesco
    Choukroun, Gabriel
    Fliser, Danilo
    Moecks, Joachim
    Wiggenhauser, Alfons
    [J]. NEPHROLOGY DIALYSIS TRANSPLANTATION, 2014, 29 : 491 - 491
  • [10] Consistent pharmacokinetic properties of CERA (continuous erythropoietin receptor activator) in healthy volunteers and in patients with CKD
    Macdougall, IC
    Reigner, B
    Dougherty, FC
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2006, 47 (04) : A41 - A41
12345